DIETARY SUPPLEMENTS AND HERBAL PRODUCTS DURING ANTICANCER TREATMENT: PREVALENCE, INTERACTIONS AND THE PROBLEM OF NON-DISCLOSURE. A NARRATIVE REVIEW
Authors:
- Agata KotlowskaAKAgata Kotlowska
- Julia LenkiewiczJLJulia Lenkiewicz
- Wiktoria NapiórkowskaWNWiktoria Napiórkowska
- Marcin TrzcińskiMTMarcin Trzciński
- Oliwia LenkiewiczOLOliwia Lenkiewicz
- Aleksandra Izabela MasłowskaAMAleksandra Izabela Masłowska
- Zuzanna ChmielewskaZCZuzanna Chmielewska
- Anna Gwóźdź-BroczkowskaAGAnna Gwóźdź-Broczkowska
- Gabriela LubaGLGabriela Luba
- Dominika GalińskaDGDominika Galińska
Open Access
- 7 September 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Abstract
Objectives: Dietary supplements and herbal products are widely used by patients undergoing anticancer treatment, and a considerable proportion of this use is never mentioned to their physician. This review summarises current evidence on the prevalence of such use, the pharmacological basis of interactions with anticancer agents, and the factors underlying non-disclosure on the part of both patients and clinicians. Methods: PubMed/MEDLINE and Google Scholar were searched for publications from January 2011, and July 2026, using combinations of terms relating to dietary supplements, herbal medicine, oncological treatment, herb–drug interactions and physician–patient communication. Priority was given to systematic reviews, meta-analyses and studies conducted in populations receiving anticancer treatment. Key findings: Reported prevalence varies widely between studies, depending on which products are counted and on the populations examined. Interactions arise principally through effects on drug metabolism and transport. Patients most often cite the absence of any question from the clinician as their reason for not disclosing; clinicians, in turn, describe their own knowledge of these products as insufficient. Training programmes have been developed to address this, but their effectiveness has yet to be established. Conclusions: Interactions between anticancer agents and dietary supplements or herbal products may be clinically relevant, yet often go unrecognised because their use is not disclosed. Non-disclosure is better understood as a feature of the consultation than as a behaviour of the patient. Two forms of intervention follow: strengthening clinicians' competence, and making enquiry about supplement use routine and free of judgement.Keywords
This publication has 47 references indexed in Scilit:
- The influence of antioxidant supplementation on adverse effects and tumor interaction during radiotherapy: a systematic reviewClinical and Experimental Medicine, 2025
- Effects of training oncology physicians advising patients on complementary and integrative therapies on patient‐reported outcomes: 2‐year follow‐up of the multi‐center, cluster‐randomized KOKON‐KTO studyCancer Medicine, 2024
- Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and agingArchives of Toxicology, 2023
- Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatmentJournal of Cancer Research and Clinical Oncology, 2021
- Dietary supplement use in ambulatory cancer patients: a survey on prevalence, motivation and attitudesJournal of Cancer Research and Clinical Oncology, 2021
- Training oncology physicians to advise their patients on complementary and integrative medicine: An implementation study for a manual‐guided consultationCancer, 2020
- Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatmentEuropean Journal of Clinical Pharmacology, 2019
- Prevalence of and Factors Associated With Patient Nondisclosure of Medically Relevant Information to CliniciansJAMA Network Open, 2018
- Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patientsSupportive Care in Cancer, 2011
- Use of Alternative Medicines by Patients with OA that Adversely Interact with Commonly Prescribed MedicationsClinical Orthopaedics and Related Research, 2009